TCM
ALNY icon

TimesSquare Capital Management’s Alnylam Pharmaceuticals ALNY Stock Holding History

TimesSquare Capital Management’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-40,000
Closed -$2.05M – 250
2017
Q1 		$2.05M Sell
40,000
-158,800
-80% -$7.34M 0.01% 241
2016
Q4 		$7.44M Buy
198,800
+3,000
+2% +$126K 0.05% 224
2016
Q3 		$13.3M Buy
195,800
+15,600
+9% +$1.1M 0.09% 216
2016
Q2 		$10M Buy
180,200
+19,150
+12% +$1.21M 0.07% 214
2016
Q1 		$10.1M Buy
161,050
+400
+0.2% +$26.6K 0.07% 212
2015
Q4 		$15.1M Sell
160,650
-19,150
-11% -$1.78M 0.1% 210
2015
Q3 		$14.4M Buy
179,800
+26,700
+17% +$2.97M 0.09% 213
2015
Q2 		$18.4M Buy
153,100
+23,200
+18% +$2.77M 0.1% 214
2015
Q1 		$13.6M Buy
129,900
+500
+0.4% +$50.7K 0.07% 224
2014
Q4 		$12.6M Sell
129,400
-225,550
-64% -$20.9M 0.07% 218
2014
Q3 		$27.7M Sell
354,950
-35,900
-9% -$2.32M 0.16% 193
2014
Q2 		$24.7M Sell
390,850
-7,600
-2% -$452K 0.13% 200
2014
Q1 		$26.8M Sell
398,450
-204,450
-34% -$15.8M 0.14% 194
2013
Q4 		$38.8M Sell
602,900
-19,900
-3% -$1.19M 0.2% 172
2013
Q3 		$39.9M Buy
+622,800
New +$31M 0.22% 163

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

TimesSquare Capital Management's ALNY Position: Q2 2017 in Review

TimesSquare Capital Management sold out of Alnylam Pharmaceuticals (ALNY) in Q2 2017, closing a stake of 40,000 shares — an estimated $2.05M sold.

TimesSquare Capital Management first reported a position in ALNY in Q3 2013 and held it in 15 quarters. The position peaked at $39.9M in Q3 2013. 226 funds tracked by Wall St. Rank hold ALNY as of Q2 2017.

  • TimesSquare Capital Management reported no remaining Alnylam Pharmaceuticals position as of Q2 2017 after selling out during the quarter.
  • TimesSquare Capital Management sold 40,000 Alnylam Pharmaceuticals shares in Q2 2017, an estimated $2.05M.
  • TimesSquare Capital Management first reported a position in Alnylam Pharmaceuticals in Q3 2013 and held it in 15 quarters.
  • TimesSquare Capital Management's Alnylam Pharmaceuticals position peaked at $39.9M in Q3 2013.
  • 226 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2017.

Based on TimesSquare Capital Management's 13F filing for Q2 2017, filed 10 Aug 2017.